JP2024514974A5 - - Google Patents
Info
- Publication number
- JP2024514974A5 JP2024514974A5 JP2023565502A JP2023565502A JP2024514974A5 JP 2024514974 A5 JP2024514974 A5 JP 2024514974A5 JP 2023565502 A JP2023565502 A JP 2023565502A JP 2023565502 A JP2023565502 A JP 2023565502A JP 2024514974 A5 JP2024514974 A5 JP 2024514974A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179799P | 2021-04-26 | 2021-04-26 | |
| US63/179,799 | 2021-04-26 | ||
| US202163287655P | 2021-12-09 | 2021-12-09 | |
| US63/287,655 | 2021-12-09 | ||
| PCT/US2022/026131 WO2022232016A2 (en) | 2021-04-26 | 2022-04-25 | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514974A JP2024514974A (ja) | 2024-04-03 |
| JP2024514974A5 true JP2024514974A5 (enExample) | 2025-04-25 |
Family
ID=83848607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565502A Pending JP2024514974A (ja) | 2021-04-26 | 2022-04-25 | Ａｄｇｒｅ２及び／またはｃｌｅｃ１２ａを標的とするキメラ受容体及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12331129B2 (enExample) |
| EP (1) | EP4330275A4 (enExample) |
| JP (1) | JP2024514974A (enExample) |
| KR (1) | KR20240005720A (enExample) |
| AU (1) | AU2022267219A1 (enExample) |
| BR (1) | BR112023022297A2 (enExample) |
| CA (1) | CA3212596A1 (enExample) |
| CL (1) | CL2023003185A1 (enExample) |
| CO (1) | CO2023015212A2 (enExample) |
| EC (1) | ECSP23081501A (enExample) |
| IL (1) | IL306141A (enExample) |
| MX (1) | MX2023012681A (enExample) |
| PE (1) | PE20250158A1 (enExample) |
| TW (1) | TW202305004A (enExample) |
| WO (1) | WO2022232016A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022266583A1 (en) | 2021-04-26 | 2023-10-19 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
| PE20241789A1 (es) * | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| CN120152735A (zh) * | 2022-10-25 | 2025-06-13 | 武田药品工业株式会社 | Adgre2嵌合受体nk细胞组合物和使用方法 |
| EP4713363A1 (en) * | 2023-05-15 | 2026-03-25 | Syzygymed Inc | Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof |
| US20250361317A1 (en) * | 2024-05-24 | 2025-11-27 | Janssen Biotech, Inc. | Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19 |
| US20260144885A1 (en) * | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Anti-lrrc15 antibodies and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US20020018783A1 (en) | 1997-03-20 | 2002-02-14 | Michel Sadelain | Fusion proteins of a single chain antibody and cd28 and uses thereof |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US9260525B2 (en) * | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| AU2016355206A1 (en) * | 2015-11-19 | 2018-05-24 | Abbvie Stemcentrx Llc | Novel anti-EMR2 antibodies and methods of use |
| EP3344263A4 (en) | 2016-08-04 | 2020-07-01 | Memorial Sloan-Kettering Cancer Center | CANCER ANTIGEN TARGETS AND USES THEREOF |
| JOP20190187A1 (ar) * | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| IL326873A (en) | 2017-12-29 | 2026-04-01 | Memorial Sloan Kettering Cancer Center | Enhanced chimeric antigen receptors and uses thereof |
| US11951129B2 (en) | 2018-01-09 | 2024-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compositions and methods for targeting CLEC12A-expressing cancers |
| SG11202007622SA (en) | 2018-02-11 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| TWI754157B (zh) * | 2018-07-25 | 2022-02-01 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｔｉｇｉｔ抗體及其用途 |
| EP3880247A4 (en) | 2018-11-13 | 2022-10-26 | JN Biosciences, LLC | Bispecific antibodies for activation of immune cells |
| JP7711945B2 (ja) * | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| US20200392230A1 (en) * | 2019-05-14 | 2020-12-17 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| EP3969482A1 (en) | 2019-05-16 | 2022-03-23 | University of Washington | Lockr-mediated recruitment of car t cells |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| PE20241789A1 (es) | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| AU2022266583A1 (en) | 2021-04-26 | 2023-10-19 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
-
2022
- 2022-04-25 JP JP2023565502A patent/JP2024514974A/ja active Pending
- 2022-04-25 IL IL306141A patent/IL306141A/en unknown
- 2022-04-25 BR BR112023022297A patent/BR112023022297A2/pt unknown
- 2022-04-25 PE PE2023002927A patent/PE20250158A1/es unknown
- 2022-04-25 MX MX2023012681A patent/MX2023012681A/es unknown
- 2022-04-25 WO PCT/US2022/026131 patent/WO2022232016A2/en not_active Ceased
- 2022-04-25 US US17/728,183 patent/US12331129B2/en active Active
- 2022-04-25 KR KR1020237037607A patent/KR20240005720A/ko active Pending
- 2022-04-25 EP EP22796477.2A patent/EP4330275A4/en active Pending
- 2022-04-25 CA CA3212596A patent/CA3212596A1/en active Pending
- 2022-04-25 AU AU2022267219A patent/AU2022267219A1/en active Pending
- 2022-04-26 TW TW111115910A patent/TW202305004A/zh unknown
-
2023
- 2023-10-25 EC ECSENADI202381501A patent/ECSP23081501A/es unknown
- 2023-10-25 CL CL2023003185A patent/CL2023003185A1/es unknown
- 2023-11-09 CO CONC2023/0015212A patent/CO2023015212A2/es unknown
-
2025
- 2025-04-22 US US19/185,375 patent/US20250250356A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7241133B2 (ja) | Ｃｄ２０抗原を標的とするキメラ抗原受容体の構築およびその遺伝子改変ｔ細胞の活性同定 | |
| US20250296970A1 (en) | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy | |
| JP7212222B2 (ja) | Ｃｄ１９及びｃｄ２０を標的とする組み合わされたキメラ抗原受容体並びにその適用 | |
| TWI800506B (zh) | 免疫結合物 | |
| JP2022105558A (ja) | 新規のポリペプチド | |
| JP2022506598A5 (enExample) | ||
| JP2017522893A5 (enExample) | ||
| CN1852976B (zh) | 结合构建体及其使用方法 | |
| JP2020525536A5 (enExample) | ||
| JP2017527275A5 (enExample) | ||
| JP2022543742A5 (enExample) | ||
| JP2022542543A5 (enExample) | ||
| JP2017522882A5 (enExample) | ||
| JP2017537925A5 (enExample) | ||
| JP2019527537A5 (enExample) | ||
| JP2019515661A5 (enExample) | ||
| JP2018512153A5 (enExample) | ||
| EP2321345A1 (en) | Multi-specific binding proteins targeting b cell disorders | |
| US11945878B2 (en) | Switch molecule and switchable chimeric antigen receptor | |
| CA2962603A1 (en) | Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof | |
| JP2023058415A (ja) | Ｃｄ７０と結合する抗体、その調製および使用 | |
| JP2022513372A5 (enExample) | ||
| JP2023539591A5 (enExample) | ||
| US20260042857A1 (en) | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence | |
| WO2007102200A1 (ja) | 抗ｃｄ２０モノクローナル抗体 |